左卡尼汀联合阿托伐他汀对缺血性慢性心力衰竭患者炎性因子及心功能影响

目的：探讨左卡尼汀联合阿托伐他汀对缺血性慢性心力衰竭患者炎性因子及心功能影响.方法：102例缺血性心脏病合并心力衰竭患者随机分为实验组、阿托伐他汀组及对照组,每组34例,对照组常规治疗; 阿托伐他汀组在对照组治疗方法基础上,口服阿托伐他汀钙; 实验组在对照组治疗方法基础上,加用左卡尼汀、阿托伐他汀钙.观察3组治疗前后TNF-α,IL-6,CRP及心功能改变.结果：实验组、阿托伐他汀组治疗后TNF-α,IL-6,CRP水平较治疗前显著降低（P〈0.01）; 实验组治疗后TNF-α,IL-6,CRP水平与对照组治疗后比较亦显著降低（P〈0.05）.阿托伐他汀组治疗后IL-6水平与对照组治疗后比较亦显著降低（P〈0.05）.实验组患者治疗后LVEF,LVEDd,NYHA分级较治疗前及阿托伐他汀组、对照组治疗后明显改善（P〈0.05）; 阿托伐他汀组、对照组治疗后NYHA分级较治疗前明显改善（P〈0.05）.结论：左卡尼汀联合阿托伐他汀通过改善心肌能量供应,降低心衰炎性反应,从而改善缺血性心衰患者的心功能.

Effects on inflammatory factor and heart function to chronic ischemic cardiac failure in treatment with Levocarnitine combined atorvastatin

AIM：To investigate the effects on inflammatory factor and heart function to chronic ischemic cardiac failure in treatment with levocarnitine combined atorvastatin.METHODS：102 patients with chronic ischemic cardiac failure were randomized into 3 groups：test group,atorvastatin group and control group.All group were receive the same conventional therapy and based the conventional therapy,the patients in atorvastatin group were administered atorvastatin and Levocarnitine combined atorvastatin in test goup.TNF-α,IL-6,CRP and heart function in all group were measured in all group.RESULTS：The levels of TNF-α,IL-6 and CRP in 3 groups were improved significantly after 2-week treatment.The levels of TNF-α,IL-6 and CRP in test group were lower than those of control group（P0.01）.The levels of IL-6 in atorvastatin group were lower than those of test group（P0.05）.The LVEF,LVEd and NYHA classification in test group were improved significantly when compared with before treatment,atorvastatin group and control group（P0.05）.NYHA classifications in atorvastatin group and control group were improved significantly after 2-week therapy（P0.05）.CONCLUSION：Levocarnitine combined atorvastatin can improve heart function by enhancing heart energy supply and decrease heart function inflammatory response.